Please login to the form below

Not currently logged in


This page shows the latest Fanapt news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs sleep pattern drug for blind

FDA panel backs sleep pattern drug for blind

Polymeropoulos. Vanda previously developed a schizophrenia treatment called Fanapt (iloperidone) which is licensed in North America to Novartis but has failed to make much headway in the market since its launch

Latest news

  • Vanda withdraws EU application for schizophrenia drug Vanda withdraws EU application for schizophrenia drug

    Despite the struggle for approval in the EU, the drug has been available for people with schizophrenia in the US since 2009, where it is sold under the brand name Fanapt.

  • Next generation

    Iloperidone. Fanapt (Novartis). Schizophrenia. US. Levodopa/benserazide. Co-Beneldopa (Teva Pharmaceuticals)  . Parkinson's disease.

  • US launch for Novartis' Fanapt

    Novartis has launched schizophrenia treatment Fanapt (iloperidone) in the US, for acute treatment of schizophrenia in adults. ... In clinical trials, Fanapt was shown to be effective for the symptoms of schizophrenia.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...